Clinical Trial Update: Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer [NA]

View source ↗

Summary

A terminated clinical trial used dynamic contrast-enhanced MRI to measure the effects of pazopanib in metastatic kidney cancer, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Votrient (Pazopanib)

Snippet

Sponsor: University of Chicago | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | NA | Status: TERMINATED | Results posted: 2017-06-08